Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company’s product development programs at 2:00 p.m. EST on Wednesday, Nov. 28, 2007, at the Lazard Capital Markets 4th Annual Healthcare Conference in New York City.

The update will include information about Geron’s portfolio of anti-cancer therapies, including its telomerase inhibitor drug (GRN163L) and telomerase therapeutic vaccine (GRNVAC1). The presentation will also include a review of the company’s human embryonic stem cell (hESC) development programs for spinal cord injury (GRNOPC1), heart disease (GRNCM1) and diabetes (GRNIC1).

An audio and slide Webcast of the presentation will be available at the following Website address: http://www.wsw.com/webcast/lz4/gern/. A replay will be available at this address within 24 hours of the presentation and for a period of 30 days.

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. For more information, visit www.geron.com.

Contacts:

Geron
David L. Greenwood, Chief Financial Officer, 650-473-7765
info@geron.com
or
Media and Investors:
Russo Partners LLC
David Schull, 858-717-2310
david.schull@russopartnersllc.com
Tracey Milani, 619-814-3511
tracey.milani@russopartnersllc.com